Literature DB >> 26408505

Human induced pluripotent stem cells in Parkinson's disease: A novel cell source of cell therapy and disease modeling.

Wen Li1, Shengdi Chen2, Jia-Yi Li3.   

Abstract

Human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs) are two novel cell sources for studying neurodegenerative diseases. Dopaminergic neurons derived from hiPSCs/hESCs have been implicated to be very useful in Parkinson's disease (PD) research, including cell replacement therapy, disease modeling and drug screening. Recently, great efforts have been made to improve the application of hiPSCs/hESCs in PD research. Considerable advances have been made in recent years, including advanced reprogramming strategies without the use of viruses or using fewer transcriptional factors, optimized methods for generating highly homogeneous neural progenitors with a larger proportion of mature dopaminergic neurons and better survival and integration after transplantation. Here we outline the progress that has been made in these aspects in recent years, particularly during the last year, and also discuss existing issues that need to be addressed.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Disease modeling; Dopaminergic differentiation; Induced pluripotent stem cells; Neural transplantation; Parkinson's disease; Reprogramming

Mesh:

Substances:

Year:  2015        PMID: 26408505     DOI: 10.1016/j.pneurobio.2015.09.009

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  12 in total

Review 1.  Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Authors:  Kai-C Sonntag; Bin Song; Nayeon Lee; Jin Hyuk Jung; Young Cha; Pierre Leblanc; Carolyn Neff; Sek Won Kong; Bob S Carter; Jeffrey Schweitzer; Kwang-Soo Kim
Journal:  Prog Neurobiol       Date:  2018-04-11       Impact factor: 11.685

Review 2.  Novel therapeutic approaches: Rett syndrome and human induced pluripotent stem cell technology.

Authors:  Mohan Gomathi; Vellingiri Balachandar
Journal:  Stem Cell Investig       Date:  2017-03-02

3.  Induced pluripotent stem cells in rat models of Parkinson's disease: A systematic review and meta-analysis.

Authors:  Yunxia Zhang; Meiling Ge; Qiukui Hao; Birong Dong
Journal:  Biomed Rep       Date:  2018-01-30

Review 4.  Blood-brain barrier dysfunction and recovery after ischemic stroke.

Authors:  Xiaoyan Jiang; Anuska V Andjelkovic; Ling Zhu; Tuo Yang; Michael V L Bennett; Jun Chen; Richard F Keep; Yejie Shi
Journal:  Prog Neurobiol       Date:  2017-10-05       Impact factor: 11.685

5.  Ginsenoside Rd and ginsenoside Re offer neuroprotection in a novel model of Parkinson's disease.

Authors:  Xinmu Zhang; Yingzi Wang; Cheng Ma; Yan Yan; Yang Yang; Xin Wang; Wolf-Dieter Rausch
Journal:  Am J Neurodegener Dis       Date:  2016-03-01

Review 6.  Postmortem Studies of Fetal Grafts in Parkinson's Disease: What Lessons Have We Learned?

Authors:  Jia-Yi Li; Wen Li
Journal:  Front Cell Dev Biol       Date:  2021-05-13

7.  Effects of Feeder Cells on Dopaminergic Differentiation of Human Embryonic Stem Cells.

Authors:  Zhenqiang Zhao; Yanlin Ma; Zhibin Chen; Qian Liu; Qi Li; Deyan Kong; Kunxiong Yuan; Lan Hu; Tan Wang; Xiaowu Chen; Yanan Peng; Weimin Jiang; Yanhong Yu; Xinfeng Liu
Journal:  Front Cell Neurosci       Date:  2016-12-20       Impact factor: 5.505

Review 8.  Priming of the Cells: Hypoxic Preconditioning for Stem Cell Therapy.

Authors:  Zheng Z Wei; Yan-Bing Zhu; James Y Zhang; Myles R McCrary; Song Wang; Yong-Bo Zhang; Shan-Ping Yu; Ling Wei
Journal:  Chin Med J (Engl)       Date:  2017-10-05       Impact factor: 2.628

Review 9.  The Future of Surgical Treatments for Parkinson's Disease.

Authors:  Darrin J Lee; Andres M Lozano
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

Review 10.  Stem cell therapy for Parkinson's disease using non-human primate models.

Authors:  Zhen-Zhen Chen; Yu-Yu Niu
Journal:  Zool Res       Date:  2019-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.